Senores Pharma to acquire 100% of Apnar Pharma for around Rs 91 cr

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.5%Reaction day

₹817.00

prior close

₹825.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.6%+1.1% vs market

Pharmaceuticals peers, median of 159sector-0.4%+0.9% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-1.2

15m

-1.6

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.5-0.6+1.1-0.4+0.9

Next day

-2.2-1.5-0.7-1.2-1.0

-2.0-1.8-0.1-1.3-0.7

-1.9-0.6-1.3-0.4-1.5

+0.4+0.8-0.4+0.1+0.3

-1.5+0.8-2.3+0.3-1.7

-0.7-0.2-0.5-0.6-0.2

15d

+5.5+1.1+4.5+0.9+4.6

-3.7-3.5-0.1-2.5-1.2

-3.2-3.2+0.1-4.3+1.1

-8.3-12.8+4.4-11.5+3.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Approved by Management Committee on Dec 15, 2025. Senores Pharma will acquire 100% of Apnar Pharma Private Limited, a generic formulations maker with US FDA, UK-MHRA and Health Canada approved facility near Vadodara. Total enterprise value about Rs 91 crores, comprising Rs 76 cr debt assumed and Rs 15 cr cash in two tranches (75% by March 2026, 25% by Q2 FY2027). Apnar turnover was about Rs 14.2 cr in FY25.

Likely market impact

Adds a regulatory-approved manufacturing unit and expands generic formulations footprint; cash outflow is modest as most of the value is debt takeover.